Last reviewed · How we verify
Topical Non-Antibiotic Ointment
A topical non-antibiotic ointment that promotes wound healing and tissue repair through moisturization and barrier protection without antimicrobial agents.
A topical non-antibiotic ointment that promotes wound healing and tissue repair through moisturization and barrier protection without antimicrobial agents. Used for Minor wounds and abrasions, Skin irritation and inflammation.
At a glance
| Generic name | Topical Non-Antibiotic Ointment |
|---|---|
| Also known as | Refresh PM |
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
This formulation is designed to support the natural healing process by maintaining a moist wound environment and protecting the affected area from external contaminants. Non-antibiotic topical ointments typically work through occlusive and emollient properties rather than direct antimicrobial action, making them suitable for minor wounds, abrasions, and skin irritation where infection risk is low.
Approved indications
- Minor wounds and abrasions
- Skin irritation and inflammation
Common side effects
- Local skin irritation
- Allergic contact dermatitis
- Maceration of surrounding skin
Key clinical trials
- Assessing Post-operative Outcomes After Children's Sistrunk Procedure With or Without a Drain (NA)
- The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal (PHASE3)
- Dropless Pars Plana Vitrectomy Study (PHASE4)
- A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries (PHASE1, PHASE2)
- A Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries (PHASE1, PHASE2)
- Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds (PHASE1, PHASE2)
- The Study on Bacterial Load Following Open-to-air Management in Burn Patients. (NA)
- Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: